Page 32 - Covid_NL_11_9_21

key role in facilitating viral entry and infection. Most of the neutralising antibodies produced by our body, target the RBD.
In previous reports, an earlier version of the vaccine candidate was found to be stable at 37°C for a month without losing its shape, and withstand transient exposure to temperatures as high as 100°C. This was also true of the current, improved versions. Such vaccines are especially useful in countries like India where cold storage and transportation are expensive and challenging. One of the improved formulations is being rapidly moved to clinical development.
Contact info:
varadar@iisc.ac.in
Website link:
https://iisc.ac.in/fighting-covid-19-viral-variants-with-a-heat-tolerant-vaccine/
***
VOL. IV ISSUE 10
VIGYAN PRASAR 28
COVID-19 SCIENCE & TECHNOLOGY EFFORTS IN INDIA